GlaxoSmithKline Plc (GSK) said it failed in its second attempt to win U.S. approval for MenHibrix, an experimental combination meningitis vaccine. The Food and Drug Administration notified Glaxo that it needs more information before it can approve the drug, the London-based drugmaker said today in a statement. The company received its first so-called complete response letter on the vaccine in June 2010. Glaxo “will work to respond to the questions posed by the FDA,” the company said in the statement.
